More precise and consumer-friendly biomarker detection technologies are coming to market at a pace that can help users gain rich insight into their health and well-being from anywhere and at any time. This is especially important when it comes to preventive healthcare.
Innovation hub and startup engagement models in the life sciences can take one of a few flavors with equity investments, commercial partnerships and accelerator programs covering most of the cases.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Startups are turning to voice data as they try to develop tools to detect a wide range of diseases. One startup, Vocalis Health, is working with Mayo Clinic to identify voice-based biomarkers for pulmonary hypertension.
Alphabet’s “moonshot” subsidiary X shared that it failed to find a single biomarker for depression and anxiety. But the company still plans to make its research, which included developing portable EEGs, available to the public.
The company, which was founded in 2014 by a team including genetics pioneer Leroy Hood, raised more than $50 million over its existence from investors including Maveron, Polaris Partners and ARCH Venture Partners.
A new report shows a steady growth in so-called "basket studies" in oncology, along with growing interest by the drug industry.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.